Nursing care of patients receiving Campath.
Monoclonal antibodies are focused therapies with unique infusion-related complications. Campath (alemtuzumab, Berlex Laboratories, Richmond, CA) is indicated for the treatment of refractory chronic lymphocytic leukemia and has a complicated administration schedule, severe infusion-related toxicity, and profound immunosuppressive capability. Ambulatory cancer care is challenging simply because of the complex nature of the disease. Management of complicated therapies, such as Campath, stretches resources and requires a coordinated effort by the healthcare team for successful patient outcomes.
Seeley
Karen
K
seelkm@stlo.smhs.com
DeMeyer
Elaine
E
D000074323:Alemtuzumab; D000553:Ambulatory Care; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006801:Humans; D007165:Immunosuppression Therapy / Q000451:nursing; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D009732:Nursing Care; D010347:Patient Care Planning; D010353:Patient Education as Topic
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000074323:Alemtuzumab